Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve the treatment of children who have recessive dystrophic epidermolysis bullosa.

NHS England is working with the National Institute for Health and Care Excellence (NICE) on the evaluation of two products for Epidermolysis Bullosa (EB), birch bark extract for skin wounds associated with dystrophic and junctional EB and the gene therapy Beremagene geperpavec for skin wounds associated with dystrophic EB. If any of these treatments are given a positive recommendation by NICE, NHS England will ensure that service provision is in place to deliver these treatments in line with the terms of the NICE mandate.